Correlation of GREB1 mRNA with protein expression in breast cancer: Validation of a novel GREB1 monoclonal antibody

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 371-380

  Hnatyszyn, H J ^a   Liu, M ^a   Hilger, A ^b   Herbert, L ^a   Gomez Fernandez, C R ^a   Jorda, M ^a   Thomas, D ^b   Rae, J M ^b   El Ashry, D ^a   Lippman, M E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

GREB1; Immunohistochemistry; Monoclonal antibody; mRNA Protein correlation.

Indexed keywords

CELL PROTEIN; ESTROGEN RECEPTOR ALPHA; GENE REGULATED BY ESTROGEN IN BREAST CANCER 1 MONOCLONAL ANTIBODY; GENE REGULATED BY ESTROGEN IN BREAST CANCER 1 PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTRADIOL; GREB1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; VALIDATION PROCESS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; REPRODUCIBILITY; RNA INTERFERENCE; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 77955655628     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0584-x     Document Type: Article

References (18)

1. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2(3):205-213.
2. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92:141-149.
3. Ghosh MG, Thompson DA, Weigel RJ (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormoneresponsive breast cancer. Cancer Res 60(22):6367-6375.
4. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2):151-159.
5. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359-377.
6. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410.
7. Zabel U, Henkel T, Silva MS, Baeuerle PA (1993) Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. EMBO J 12(1):201-211.
8. Nedergaard L, Christensen L, Rasmussen BB, Jacobsen GK (1996) Comparison of two monoclonal antibodies for the detection of estrogen receptors in primary breast carcinomas. Pathol Res Pract 192(10):983-988.
9. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598-6607.
10. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20(14):3095-3105.
11. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481.
12. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145. (Pubitemid 350003059)
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18-43. (Pubitemid 46174133)
14. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D (2006) Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66(7):3903-3911.
15. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J et al (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28(6):803-814.
16. Leung LK, Wang TT (1999) Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. Br J Cancer 81(3):387-392.
17. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF et al (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239.
18. Singer CF, Kostler WJ, Hudelist G (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta 1786(2):105-113.